New and translational perspectives of oestrogen deprivation in breast cancer

Molecular and Cellular Endocrinology

Volumn 340, Issue 2, 2011, Pages 137-141

  Dunbier, Anita K ^a,b   Martin, Lesley Ann ^b   Dowsett, Mitch ^a,b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Aromatase; Aromatase inhibitors; Breast cancer; Oestrogen

Indexed keywords

ANASTROZOLE; AROMATASE; ERLOTINIB; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; GEFITINIB; KI 67 ANTIGEN; LAPATINIB; LETROZOLE; TAMOXIFEN; TRASTUZUMAB;

ADJUVANT THERAPY; APOPTOSIS; BREAST CANCER; CANCER RESISTANCE; CANCER SURVIVAL; DRUG MECHANISM; DRUG RESPONSE; DRUG SENSITIVITY; ENZYME INHIBITION; ESTROGEN SYNTHESIS; GENE EXPRESSION; HORMONAL THERAPY; HUMAN; PREOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; ESTROGENS; FEMALE; HUMANS; RECEPTORS, ESTROGEN; TIME FACTORS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 79960264727     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2010.12.034     Document Type: Review

References (32)

1. Johnston S.R., Dowsett M. Aromatase inhibitors for breast cancer: lessons from the laboratory. Nat. Rev. Cancer 2003, 3:821-831.
2. Kendall A., Folkerd E.J., Dowsett M. Influences on circulating oestrogens in postmenopausal women: relationship with breast cancer. J. Steroid Biochem. Mol. Biol. 2007, 103:99-109.
3. Simpson E.R., Dowsett M. Aromatase and its inhibitors: significance for breast cancer therapy. Recent Prog. Horm. Res. 2002, 57:317-338.
4. Dunbier A.K., Anderson H., Ghazoui Z., Folkerd E.J., A'Hern R., Crowder R.J., Hoog J., Smith I.E., Osin P., Nerurkar A., Parker J.S., Perou C.M., Ellis M.J., Dowsett M. Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women. J. Clin. Oncol. 2010, 28:1161-1167.
5. Dowsett M., Smith I.E., Ebbs S.R., Dixon J.M., Skene A., A'Hern R., Salter J., Detre S., Hills M., Walsh G. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J. Natl. Cancer Inst. 2007, 99:167-170.
6. Haynes B.P., Straume A.H., Geisler J., A'Hern R., Helle H., Smith I.E., Lonning P.E., Dowsett M. Intratumoral estrogen disposition in breast cancer. Clin. Cancer Res. 2010, 16:1790-1801.
7. Masamura S., Santner S.J., Heitjan D.F., Santen R.J. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J. Clin. Endocrinol. Metab. 1995, 80:2918-2925.
8. Chan C.M., Martin L.A., Johnston S.R., Ali S., Dowsett M. Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation. J. Steroid Biochem. Mol. Biol. 2002, 81:333-341.
9. Martin L.A., Farmer I., Johnston S.R., Ali S., Marshall C., Dowsett M. Enhanced estrogen receptor (ER) alpha ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J. Biol. Chem. 2003, 278:30458-30468.
10. Martin L.A., Pancholi S., Chan C.M., Farmer I., Kimberley C., Dowsett M., Johnston S.R. The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling. Endocr. Relat. Cancer 2005, 12:1017-1036.
11. Dowsett M., Stein R.C., Coombes R.C. Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients. J. Steroid Biochem. Mol. Biol. 1992, 43:155-159.
12. Song R.X., Mor G., Naftolin F., McPherson R.A., Song J., Zhang Z., Yue W., Wang J., Santen R.J. Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. J. Natl. Cancer Inst. 2001, 93:1714-1723.
13. Arnedos M., Drury S., Afentakis M., Hills M., Salter J., Smith I.E., Dowsett M. Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in ER-positive breast cancer. J. Clin. Oncol. 2010, 28.
14. Leary A.F., Drury S., Detre S., Pancholi S., Lykkesfeldt A.E., Martin L.A., Dowsett M., Johnston S.R. Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance. Clin. Cancer Res. 2010, 16:1486-1497.
15. Cristofanilli M., Valero V., Mangalik A., Royce M., Rabinowitz I., Arena F.P., Kroener J.F., Curcio E., Watkins C., Bacus S., Cora E.M., Anderson E., Magill P.J. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clin. Cancer Res. 2010, 16:1904-1914.
16. Mita M., Bono J., Mita A. A phase II and biologic correlative study investigating anastrozole (A) in combination with gefitinib (G) in postmenopausal patients with estrogen receptor positive (ER) metastatic breast carcinoma (MBC) who have previously failed hormonal therapy. Breast Cancer Res. Treat. 2005, 94(Suppl. 1):1117.
17. Kaufman B., Mackey J.R., Clemens M.R., Bapsy P.P., Vaid A., Wardley A., Tjulandin S., Jahn M., Lehle M., Feyereislova A., Revil C., Jones A. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J. Clin. Oncol. 2009, 27:5529-5537.
18. Johnston S., Pippen J., Pivot X., Lichinitser M., Sadeghi S., Dieras V., Gomez H.L., Romieu G., Manikhas A., Kennedy M.J., Press M.F., Maltzman J., Florance A., O'Rourke L., Oliva C., Stein S., Pegram M. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J. Clin. Oncol. 2009, 27:5538-5546.
19. Dowsett M., Ebbs S.R., Dixon J.M., Skene A., Griffith C., Boeddinghaus I., Salter J., Detre S., Hills M., Ashley S., Francis S., Walsh G., Smith I.E. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer-a study from the IMPACT trialists. J. Clin. Oncol. 2005, 23:2477-2492.
20. Smith I.E., Dowsett M., Ebbs S.R., Dixon J.M., Skene A., Blohmer J.U., Ashley S.E., Francis S., Boeddinghaus I., Walsh G. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J. Clin. Oncol. 2005, 23:5108-5116.
21. Baum M., Budzar A.U., Cuzick J., Forbes J., Houghton J.H., Klijn J.G., Sahmoud T. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002, 359:2131-2139.
22. Baum M., Buzdar A., Cuzick J., Forbes J., Houghton J., Howell A., Sahmoud T. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003, 98:1802-1810.
23. Mackay A., Urruticoechea A., Dixon J.M., Dexter T., Fenwick K., Ashworth A., Drury S., Larionov A., Young O., White S., Miller W.R., Evans D.B., Dowsett M. Molecular response to aromatase inhibitor treatment in primary breast cancer. Breast Cancer Res. 2007, 9:R37.
24. Miller W.R., Larionov A., Renshaw L., Anderson T.J., Walker J.R., Krause A., Sing T., Evans D.B., Dixon J.M. Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole. J. Clin. Oncol. 2009, 27:1382-1387.
25. Miller W.R., Larionov A.A., Renshaw L., Anderson T.J., White S., Murray J., Murray E., Hampton G., Walker J.R., Ho S., Krause A., Evans D.B., Dixon J.M. Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole. Pharmacogenet. Genomics 2007, 17:813-826.
26. Anderson H., A'Hern R., Salter J., Hills M., Detre S., Larionov A., Skene A., Miller W.R., Dixon J.M., Smith I.E., Dowsett M. Early acquired resistance to endocrine therapy: extending the neoadjuvant model. Cancer Res. 2010, 69:2005.
27. Smith I.E., Walsh G., Skene A., Llombart A., Mayordomo J.I., Detre S., Salter J., Clark E., Magill P., Dowsett M. A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J. Clin. Oncol. 2007, 25:3816-3822.
28. Bunone G., Briand P.A., Miksicek R.J., Picard D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. 1996, 15:2174-2183.
29. Joel P.B., Smith J., Sturgill T.W., Fisher T.L., Blenis J., Lannigan D.A. pp90rsk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167. Mol. Cell. Biol. 1998, 18:1978-1984.
30. Kurokawa H., Lenferink A.E., Simpson J.F., Pisacane P.I., Sliwkowski M.X., Forbes J.T., Arteaga C.L. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res. 2000, 60:5887-5894.
31. Nakajima T., Fukamizu A., Takahashi J., Gage F.H., Fisher T., Blenis J., Montminy M.R. The signal-dependent coactivator CBP is a nuclear target for pp90RSK. Cell 1996, 86:465-474.
32. Smith C.L., Onate S.A., Tsai M.J., O'Malley B.W. CREB binding protein acts synergistically with steroid receptor coactivator-1 to enhance steroid receptor-dependent transcription. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:8884-8888.